	0	1	P	Ē,	ک
PE.	JUL	1	3	2004	61103
B				Lha	ŭ)

EV 533068772 US

USPS Express Mail Label Number

July 13, 2004

Date of Deposit

certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

PATENT

Customer Number 22,852 Attorney Docket No. 04189.0083-06000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Notice of Allowance Dated: 04/13/2004		
In re Application of: Thompson et al.) Confirmation No. 2193		
Serial No.: 08/482,283	Group Art Unit: 1647		
Filed: June 7, 1995	Examiner: Spector, L.		
For: NUCLEIC ACIDS ENCODING INTERLEUKIN-1 INHIBITORS AND PROCESSES FOR PREPARING INTERLEUKIN-1 INHIBITORS (Amended)			

Mail Stop Issue Fee

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Applicant encloses a copy of the Corrected Filing Receipt for the above-identified patent application, with corrections shown in red ink. Applicant requests correction of the following items.

The filing receipt states "Residence Not Provided" for inventors Charles H. Hannum, Stephen P. Eisenberg, William P. Arend, Fenneke G. Joslin, and Andreas Sommer. The complete residence information should be corrected to read:

ROBERT C. THOMPSON, BOULDER, CO;

CHARLES H. HANNUM, SUNNYVALE, CA;
STEPHEN P. EISENBERG, BOULDER, CO;
WILLIAM P. AREND, DENVER, CO;
FENNEKE G. JOSLIN, DENVER, CO;
ANDREAS SOMMER, CONCORD, CA;

The filing receipt states that the Domestic Priority data as claimed by the applicant is:

This application is a DIV of 08/319,506 10/06/1994 ABN which is a CON of 07/850,675 03/13/1992 ABN which is a CIP of 07/822,296 01/17/1992 ABN which is a CIP of 07/248,521 09/23/1988 ABN which is a CIP of 07/238,713 08/31/1988 ABN which is a CIP of 07/199,915 05/27/1988 ABN

The Domestic Priority data as claimed by the applicant should be corrected to read:

This application is a DIV of 08/319,506 10/06/1994 ABN which is a CON of 07/850,675 03/13/1992 ABN which is a CIP of 07/822,296 01/17/1992 ABN and a CIP of 07/555,274 07/19/1990 ABN and a CIP of 07/669,862 03/15/1991 ABN which is a CIP of 07/506,522 04/06/1990 now U.S. Patent No. 5,075,222 which is a CON of 07/266,531 11/03/1988 ABN which is a CIP of 07/248,521 09/23/1988 ABN which is a CIP of 07/238,713 08/31/1988 ABN which is a CIP of 07/199,915 05/27/1988 ABN

The title on the filing receipt is "NUCLEIC ACIDS ENCODING INTERLEUKIN-1 RECEPTOR ANTAGONISTS." The title of the application should be corrected to read:

NUCLEIC ACIDS ENCODING INTERLEUKIN-1 INHIBITORS AND PROCESSES FOR PREPARING INTERLEUKIN-1 INHIBITORS

Applicant respectfully requests that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: July 13, 2004

M. Paul Barker Reg. No. 32,013



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS Dox 1450 - Alexandria, Viginia 22313-1450 www.uspto.gov

FILING OR 371 ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS APPL NO. TOT CLMS IND CLMS (c) DATE 08/482,283 06/07/1995 1647 3612 19

04189.0083-06

22852

FINNEGAN, HENDERSON, FARABOW, GARRET

1300 I STREET, NW WASHINGTON, DC 20005 APR + # anna

CONFIRMATION NO. 2193 CORRECTED FILING RECEIPT

OC000000012335088

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER, LLP

Date Mailed: 04/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

ROBERT C. THOMPSON, BOULDER, CO; CHARLES H. HANNUM, Residence Not Provided: SUNNYVALE, CA; STEPHEN P. EISENBERG, Residence Not Provided; BOULDER, CO, WILLIAM P. AREND, Residence Not Provided; DENVER CO FENNEKE G. JOSLIN, Residence Not Provided; DENVER, CO. ANDREAS SOMMER, Residence Not Provided; DANVILLE, CA;

Domestic Priority data as claimed by applicant

This application is a DIV of 08/319,506 10/06/1994 ABN which is a CON of 07/850,675 03/13/1992 ABN which is a CIP of 07/822,296 01/17/1992 ABN which is a CIP of 07/248,521 09/23/1988 ABN which is a CIP of 07/238,713 08/31/1988 ABN which is a CIP of 07/199,915 05/27/1988 ABN

and a CIP of 07/555,274 07/19/1990 ABN and a CIP of 07/669, 862 03/15/1991 ABN
Which is a CIP of 07/506,522 04/06/1990
NOW U.S. Patent No. 5,075,222
Which is a CON of 07/266,531 11/03/1988 ABN

Foreign Applications

If Required, Foreign Filing License Granted: 04/12/2004

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

DK40/K0/4/4/24

Early Publication Request: No

Title

-NUCLEIC ACIDS ENCODING INTERLEUKIN-1 RECEPTOR ANTAGONISTSNUCLEIC ACIDS ENCODING INTERLEUKIN-1 INHIBITORS AND
Preliminary Class PROCESSES FOR PREPARING INTERLEUKIN-1 INHIBITORS
424

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).